Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response
Language English Country Greece Media print
Document type Journal Article, Validation Study
PubMed
29715124
DOI
10.21873/anticanres.12546
PII: 38/5/2961
Knihovny.cz E-resources
- Keywords
- Renal cell carcinoma, microRNA, prediction, sunitinib, therapy response,
- MeSH
- Adult MeSH
- Indoles therapeutic use MeSH
- Kaplan-Meier Estimate MeSH
- Carcinoma, Renal Cell drug therapy genetics mortality MeSH
- Middle Aged MeSH
- Humans MeSH
- MicroRNAs analysis MeSH
- Biomarkers, Tumor analysis genetics MeSH
- Kidney Neoplasms drug therapy genetics mortality MeSH
- Area Under Curve MeSH
- Disease-Free Survival MeSH
- Prognosis MeSH
- Antineoplastic Agents therapeutic use MeSH
- Pyrroles therapeutic use MeSH
- ROC Curve MeSH
- Aged MeSH
- Sensitivity and Specificity MeSH
- Sunitinib MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Validation Study MeSH
- Names of Substances
- Indoles MeSH
- MicroRNAs MeSH
- Biomarkers, Tumor MeSH
- Antineoplastic Agents MeSH
- Pyrroles MeSH
- Sunitinib MeSH
BACKGROUND/AIM: Targeted therapy with the tyrosine kinase inhibitor sunitinib is used in the first line of metastatic renal cell carcinoma (mRCC) treatment. The aim of the present study was independent validation of microRNAs (miRNAs) identified in previous studies as biomarkers predicting response to sunitinib therapy. MATERIALS AND METHODS: Based on a literature search, 10 miRNAs were chosen from six relevant studies as candidates for validation: miR-155, miR-484, miR-221, miR-222, miR-425, miR-133, miR-410, miR-141, miR-628 and miR-942. Validation of these miRNAs was performed on cohort of 56 patients with mRCC with extremely good or poor response responses to sunitinib treatment using quantitative reverse transcription-polymerase chain reaction. Patients were divided into either responding (n=24) or non-responding (n=32) groups to sunitinib treatment according to Response Evaluation Criteria in Solid Tumors and progression-free survival (PFS). All patients in the responding group had PFS longer than 18 months, PFS of non-responders was shorter than 6 months in all cases. RESULTS: miR-942 and miR-133 were confirmed as being differentially expressed in tumors of responding and non-responding patients. It was not possible to validate the predictive value of other tested miRNAs, however, expression of miR-221 and miR-425 tended to be positively associated with therapeutic response (p<0.1). We further developed a model based on the combination of miR-942 and miR-133 expression, that enabled identification of non-responding patients with mRCC with sensitivity of 78% and specificity of 79% (area under the curve=0.8071). CONCLUSION: Following further independent validation, detection of these miRNAs may prevent unnecessary and costly approaches to therapy in non-responding patients with mRCC.
Biomedical Center Faculty of Medicine Charles University Pilsen Czech Republic
Central European Institute of Technology Masaryk University Brno Czech Republic
Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic
References provided by Crossref.org
